Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Molden

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 28, 2001
[Metabolic interactions with statins]E Molden, A Asberg
European Journal of Clinical Pharmacology|January 11, 2001
CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cellsE Molden, A Asberg, H Christensen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2000
Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitroE Molden, H Christensen, R B Sund
European Journal of Clinical Pharmacology|August 5, 2008
Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patientsI Rudberg, M Hermann, H Refsum, et al.
European Journal of Clinical Pharmacology|March 1, 2003
Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peelH Wangensteen, E Molden, H Christensen, et al.
European Journal of Clinical Pharmacology|June 30, 2016
Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring dataR L Smith, T Haslemo, H Refsum, et al.
The Pharmacogenomics Journal|November 14, 2012
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patientsM M Söderberg, T Haslemo, E Molden, et al.
Pharmacopsychiatry|July 28, 2006
The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugsM Hendset, T Haslemo, I Rudberg, et al.
Clinical Pharmacology and Therapeutics|July 13, 2007
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patientsI Rudberg, B Mohebi, M Hermann, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2009
Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitroI Rudberg, J L E Reubsaet, M Hermann, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 28, 2001
[Metabolic interactions with statins]E Molden, A Asberg
European Journal of Clinical Pharmacology|January 11, 2001
CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cellsE Molden, A Asberg, H Christensen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2000
Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitroE Molden, H Christensen, R B Sund
European Journal of Clinical Pharmacology|August 5, 2008
Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patientsI Rudberg, M Hermann, H Refsum, et al.
European Journal of Clinical Pharmacology|March 1, 2003
Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peelH Wangensteen, E Molden, H Christensen, et al.
European Journal of Clinical Pharmacology|June 30, 2016
Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring dataR L Smith, T Haslemo, H Refsum, et al.
The Pharmacogenomics Journal|November 14, 2012
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patientsM M Söderberg, T Haslemo, E Molden, et al.
Pharmacopsychiatry|July 28, 2006
The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugsM Hendset, T Haslemo, I Rudberg, et al.
Clinical Pharmacology and Therapeutics|July 13, 2007
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patientsI Rudberg, B Mohebi, M Hermann, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2009
Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitroI Rudberg, J L E Reubsaet, M Hermann, et al.
Pageof 2